期刊
EXPERIMENTAL HEMATOLOGY
卷 39, 期 3, 页码 282-292出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2010.11.010
关键词
-
资金
- Jacqueline Seroussi Grant
- Biokine Therapeutics Ltd. (Ness Ziona, Israel)
Objective. The chemokine receptor CXCR4 and its ligand CXCL12 are involved in the progression and dissemination of a diverse number of solid and hematological malignancies. Binding CXCL12 to CXCR4 activates a variety of intracellular signal transduction pathways that regulate cell chemotaxis, adhesion, survival, proliferation, and apoptosis. Materials and Methods. Here, we demonstrate that the CXCR4 antagonist, 4F-benzoyl-TN14003 (BKT140), but not AMD3100, exhibits a CXCR4-dependent preferential cytotoxicity toward malignant cells of hematopoietic origin. BKT140 significantly and preferentially stimulated multiple myeloma apoptotic cell death. BKT140 treatment induced morphological changes, phosphatidylserine externalization, decreased mitochondrial membrane potential, caspase-3 activation, sub-G1 arrest, and DNA double-stranded breaks. Results. In vivo, subcutaneous injections of BKT140 significantly reduced, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts. Tumors from animals treated with BKT140 were smaller in size and weights, had larger necrotic areas and high apoptotic scores. Conclusions. Taken together, these results suggest a potential therapeutic use for BKT140 in multiple myeloma and leukemia patients. (C) 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据